Surveillance of adverse events after the first trivalent inactivated influenza vaccine produced in mammalian cell culture (Flucelvax(®)) reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013-2015
- PMID: 26518405
- PMCID: PMC6500456
- DOI: 10.1016/j.vaccine.2015.10.084
Surveillance of adverse events after the first trivalent inactivated influenza vaccine produced in mammalian cell culture (Flucelvax(®)) reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013-2015
Abstract
Background: In November 2012, the first cell cultured influenza vaccine, a trivalent subunit inactivated influenza vaccine (Flucelvax(®), ccIIV3), was approved in the US for adults aged ≥ 18 years.
Objective: To assess adverse events (AEs) after ccIIV3 reported to the US Vaccine Adverse Event Reporting System (VAERS), a spontaneous reporting surveillance system.
Methods: We searched VAERS for US reports after ccIIV3 among persons vaccinated from July 1, 2013-March 31, 2015. Medical records were requested for reports classified as serious (death, hospitalization, prolonged hospitalization, disability, life-threatening-illness), and those suggesting anaphylaxis and Guillain-Barré syndrome (GBS). Physicians reviewed available information and assigned a primary clinical category using MedDRA system organ classes (SOC) to each report. Empirical Bayesian data mining was used to identify disproportional AE reporting following ccIIV3.
Results: VAERS received 629 reports following ccIIV3 of which 313 were for administration of vaccine to persons <18 years. Among 309 reports with an AE documented, 19 (6.1%) were serious and the most common categories were 152 (49.2%) general disorders and administration site conditions (mostly injection site and systemic reactions) and 73 (23.6%) immune system disorders with two reports of anaphylaxis. Four reports of GBS were submitted. Disproportional reporting was identified for 'drug administered to patient of inappropriate age.'
Conclusions: Review of VAERS reports did not identify any concerning pattern of AEs after ccIIV3. Injection site and systemic reactions were the most commonly reported AEs, similar to the pre-licensure clinical trials. Reports following ccIIV3 in persons <18 years highlight the need for education of healthcare providers regarding approved ccIIV3 use.
Keywords: Adverse event; Cell culture; Surveillance; Trivalent inactivated influenza vaccine; Vaccine safety.
Published by Elsevier Ltd.
Conflict of interest statement
Conflict of interest: None of the authors have a conflict of interest.
Similar articles
-
Adverse events after Fluzone ® Intradermal vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2011-2013.Vaccine. 2013 Oct 9;31(43):4984-7. doi: 10.1016/j.vaccine.2013.08.001. Epub 2013 Aug 29. Vaccine. 2013. PMID: 23994022 Free PMC article.
-
Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015.Vaccine. 2016 May 11;34(22):2507-12. doi: 10.1016/j.vaccine.2016.03.048. Epub 2016 Mar 23. Vaccine. 2016. PMID: 27015735 Free PMC article. Review.
-
Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.Vaccine. 2014 Nov 12;32(48):6499-504. doi: 10.1016/j.vaccine.2014.09.018. Epub 2014 Sep 22. Vaccine. 2014. PMID: 25258101
-
Postlicensure safety surveillance for high-dose trivalent inactivated influenza vaccine in the Vaccine Adverse Event Reporting System, 1 July 2010-31 December 2010.Clin Infect Dis. 2012 Jun;54(11):1608-14. doi: 10.1093/cid/cis256. Epub 2012 Mar 22. Clin Infect Dis. 2012. PMID: 22441652
-
Monitoring the safety of high-dose, trivalent inactivated influenza vaccine in the vaccine adverse event reporting system (VAERS), 2011 - 2019.Vaccine. 2020 Aug 18;38(37):5923-5926. doi: 10.1016/j.vaccine.2020.07.007. Epub 2020 Jul 21. Vaccine. 2020. PMID: 32709434 Review.
Cited by
-
Population-Based Incidence of Guillain-Barré Syndrome During Mass Immunization With Viral Vaccines: A Pooled Analysis.Front Immunol. 2022 Feb 3;13:782198. doi: 10.3389/fimmu.2022.782198. eCollection 2022. Front Immunol. 2022. PMID: 35185881 Free PMC article.
-
Summary of the NACI Supplemental Statement on Mammalian Cell Culture-Based Influenza Vaccines.Can Commun Dis Rep. 2020 Oct 1;46(10):324-332. doi: 10.14745/ccdr.v46i10a03. eCollection 2020 Oct 1. Can Commun Dis Rep. 2020. PMID: 33316000 Free PMC article.
-
New Points of Departure for More Global Influenza Vaccine Use.Vaccines (Basel). 2020 Jul 23;8(3):410. doi: 10.3390/vaccines8030410. Vaccines (Basel). 2020. PMID: 32718042 Free PMC article.
-
Monoclonal Antibody Responses after Recombinant Hemagglutinin Vaccine versus Subunit Inactivated Influenza Virus Vaccine: a Comparative Study.J Virol. 2019 Oct 15;93(21):e01150-19. doi: 10.1128/JVI.01150-19. Print 2019 Nov 1. J Virol. 2019. PMID: 31434733 Free PMC article.
-
Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax® Tetra/Flucelvax Quadrivalent®): A Review in the Prevention of Influenza.Drugs. 2019 Aug;79(12):1337-1348. doi: 10.1007/s40265-019-01176-z. Drugs. 2019. PMID: 31372959 Free PMC article. Review.
References
-
- Food and Drug Administration. November 20, 2012. Approval Letter - Flucelvax. Available at: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm3.... Accessed March 23, 2015.
-
- Doroshenko A, Halperin SA. Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines). Expert Rev Vaccines 2009. June;8(6):679–88 - PubMed
-
- Centers for Disease Control and Prevention (CDC). Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2013–2014. MMWR Recomm Rep 2013. September 20;62(RR-07):1–43. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6207a1.htm. Accessed March 23, 2015. - PubMed
-
- Grohskopf LA, Olsen SJ, Sokolow LZ, Bresee JS, Cox NJ, Broder KR, Karron RA, Walter EB; Centers for Disease Control and Prevention. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) -- United States, 2014–15 influenza season. MMWR Morb Mortal Wkly Rep 2014. August 15;63(32):691–7. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6332a3.htm. Accessed March 23, 2015 - PMC - PubMed
-
- Food and Drug Administration, Flucelvax. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedPro... Accessed on March 23, 2015.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical